Loading

Please wait...

Cyramza

Generic Name: ramucirumab (RA mue SIR ue mab)
Brand Names: Cyramza
Cyramza (ramucirumab) is used to treat gastric cancer, non-small cell lung cancer, colorectal cancer, and hepatocellular carcinoma. Includes Cyramza side effects, interactions and indications.
  • Prescription Settings
  • X

Prices and coupons of Cyramza

Set your location
for drug prices near you

Enter your zip code


Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Cyramza (ramucirumab) is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Cyramza is used to treat stomach cancer, colorectal cancer, or non-small cell lung cancer that has spread to other parts of the body, and hepatocellular carcinoma. Ramucirumab may be given alone or in combination with other cancer medicines. Cyramza is usually given after other cancer medicines have been tried without success. Cyramza can increase your risk of serious bleeding. Stop using this medicine and call your doctor at once if you have severe stomach pain, bloody or tarry stools, coughing up blood, or any heavy or unusual bleeding. Learn more

Cyramza Side Effects

Cyramza Side Effects

Note: This document contains side effect information about ramucirumab. Some of the dosage forms listed on this page may not apply to the brand name Cyramza.

For the Consumer

Applies to ramucirumab: intravenous solution

Warning

Intravenous route (Solution)

Ramucirumab increased the risk of hemorrhage and gastrointestinal hemorrhage, including severe and sometimes fatal hemorrhagic events. Permanently discontinue ramucirumab in patients who experience severe bleeding. Ramucirumab can also increase the risk of potentially fatal gastrointestinal perforation. Permanent discontinue treatment if this event occurs. Impaired wound healing may occur with antibodies inhibiting the vascular endothelial growth factor pathway. Withhold treatment prior to surgery and discontinue ramucirumab if impaired wound healing or wound healing complications occur.

Along with its needed effects, ramucirumab (the active ingredient contained in Cyramza) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking ramucirumab:

More common

  • Back pain or spasms
  • blurred vision
  • burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
  • chest pain
  • chills
  • confusion
  • convulsions
  • decreased urine output
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • fainting
  • fast, pounding, or irregular heartbeat or pulse
  • feeling of warmth
  • feeling unusually cold
  • headache
  • increased thirst
  • muscle pain or cramps
  • nausea or vomiting
  • nervousness
  • pounding in the ears
  • redness of the face, neck, arms, and occasionally, upper chest
  • shakiness in the legs, arms, hands, or feet
  • shivering
  • sweating
  • swelling of the face, ankles, or hands
  • trembling or shaking of the hands or feet
  • unusual tiredness or weakness

Less common

  • Abdominal or stomach pain, cramping, or burning
  • bleeding gums
  • bloody nose
  • cough
  • coughing up blood
  • difficulty with breathing or swallowing
  • dizziness
  • fever
  • inability to speak
  • increased menstrual flow or vaginal bleeding
  • low blood pressure or pulse
  • lower back or side pain
  • nosebleeds
  • pain in the chest, groin, or legs, especially calves of the legs
  • pain or discomfort in the arms, jaw, back, or neck
  • painful or difficult urination
  • pale skin
  • paralysis
  • prolonged bleeding from cuts
  • red or black, tarry stools
  • red or dark brown urine
  • severe constipation
  • severe headaches of sudden onset
  • severe numbness, especially on one side of the face or body
  • slurred speech
  • sore throat
  • sudden loss of coordination
  • sudden onset of shortness of breath for no apparent reason
  • sudden onset of slurred speech
  • sudden vision changes
  • sweating
  • temporary blindness
  • ulcers, sores, or white spots in the mouth
  • unconsciousness
  • unusual bleeding or bruising
  • vomiting of material that looks like coffee grounds, severe and continuing

Some side effects of ramucirumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Diarrhea

For Healthcare Professionals

Applies to ramucirumab: intravenous solution

Gastrointestinal

(20%), mucosal inflammation, GI hemorrhage events (e.g., hemorrhage, diarrhea hemorrhage, gastric hemorrhage, GI hemorrhage, hematemesis, hematochezia, hemorrhoidal hemorrhage, Mallory-Weiss syndrome, melaena, esophageal hemorrhage, rectal hemorrhage, upper GI hemorrhage) (10%)

Common (1% to 10%): Intestinal obstruction

Uncommon (0.1% to 1%): GI perforation

Immunologic

Common (1% to 10%): Anti-ramucirumab (the active ingredient contained in Cyramza) antibodies

Uncommon (0.1% to 1%): Infusion related reactions, sepsis

Dermatologic

Common (1% to 10%): Rash, Palmar-plantar erythrodysesthesia syndrome

Hematologic

Very common (10% or more): Neutropenia (54%), leukopenia (34%), thrombocytopenia (13%)

Nervous system

Common (1% to 10%): Headache

Rare (less than 0.1%): Reversible Posterior Leukoencephalopathy Syndrome (RPLS), hepatic encephalopathy

Renal

Very common (10% or more): Proteinuria (17%)

Cardiovascular

Very common (10% or more): Peripheral edema (25%), hypertension (25%)

Common (1% to 10%): Arterial thromboembolic events

Metabolic

Very common (10% or more): Hypoalbuminemia (11%)

Common (1% to 10%): Hyponatremia, hypokalemia, hypoalbuminemia

Other

Very common (10% or more): Fatigue/asthenia (57%), peripheral edema

Respiratory

Very common (10% or more): Epistaxis (31%)

Local

Common (1% to 10%): Infusion-related reactions

Genitourinary

Very common (10% or more): Proteinuria

Editorial References and Review

Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.

Source: Drugs.com Cyramza (www.drugs.com/cyramza.html).